What Clinical Trial Venture Capital Think About Clinical Trial Tech
“Even when the ROI is 10 to 13x, it still takes six years to adopt.” That’s the paradox that...
Moe Alsumidaie
Pharma Cuts Clinical Trial CSR Time by >50% With AI
AI is revolutionizing clinical documentation in clinical trials. In this interview, Anita Modi, CEO and Founder of Peer AI,...
Veeva and IQVIA: A New Era of Collaboration in Clinical Trials
In a transformative move, Veeva Systems and IQVIA, two titans in the life sciences sector, have shifted from litigation...
Why FDA’s Draft 510(k) Guidance is Forcing Sponsors to Rethink Device Submissions
The device team thought they were following the playbook. They chose a predicate that had been cleared two decades...
How Sponsors Can Win or Lose in the 510(k) Strategy Pathway
The start-up team was confident. Their Class II device had promising bench data, strong engineering, and investors eager for...
Simplifying EUCTR Disclosure: Veeva’s Unified Platform Tackles Complexity
At the 2025 Veeva R&D and Quality Summit in Madrid, Matt DeFranco, Senior Director of Disclosure Strategy at Veeva...
Navigating AI in Clinical Trials: Insights from Advarra’s Laura Russell
Advarra has launched the Council for Responsible AI in Clinical Trials to ensure the ethical use of AI in...
Streamlining Clinical Trials with BYOT Platform Consolidation
In this interview, we sit down with Jane Myles and Joe Dustin, leaders in clinical operations and digital transformation...
ImmunityBio’s Visionary Approach to Cancer Immunotherapy
In this interview with Bobby Reddy, Chief Medical Officer at ImmunityBio, we explore the company’s groundbreaking work in cancer...
FDA and EMA Push for Predicting Protocol Deviations. How Psychology Can Help
The site team was blindsided. The patient met every inclusion and exclusion criterion, showed no red flags, and even...